Skip to main content
Adam Crystal, MD, Oncology, East Watertown, MA

AdamCrystalMD

Oncology East Watertown, MA

Chief Medical Officer, C4 Therapeutics.

Dr. Crystal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Crystal's full profile

Already have an account?

  • Office

    C4 Therapeutics, Inc
    490 Arsenal Way, Suite 100
    East Watertown, MA 02472

Summary

  • Medical oncologist (MD-PhD), board certified; Industry experience in early phase oncology drug development including small molecules, IO and CAR-T; Translational research: acquired resistance to targeted therapy in lung cancer.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2013
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 2006 - 2007
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2006

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2008 - 2025

Publications & Presentations

PubMed

Press Mentions

  • Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
    Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingApril 18th, 2023
  • Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
    Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsMarch 27th, 2023
  • AACR: C4's Multiple Myeloma Data Prompts Dosing Switch, Giving Patients a Longer Treatment Reprieve
    AACR: C4's Multiple Myeloma Data Prompts Dosing Switch, Giving Patients a Longer Treatment ReprieveApril 8th, 2022
  • Join now to see all